Tracking Motor Progression and Device‐Aided Therapy Eligibility in Parkinson's Disease
ABSTRACT Objective To characterise the progression of motor symptoms and identify eligibility for device‐aided therapies in Parkinson's disease, using both the 5‐2‐1 criteria and a refined clinical definition, while examining differences across genetic subgroups.
David Ledingham +7 more
wiley +1 more source
ARTIFICIAL INTELLIGENCE MANAGEMENT AND ETHICS IN THE IMPLEMENTATION OF MECHATRONIC SYSTEMS IN THE AUTOMOTIVE INDUSTRY: CHALLENGES AND APPLIED SOLUTIONS [PDF]
Aurel Mihail Țîțu +3 more
openalex +1 more source
Network Localization of Fatigue in Multiple Sclerosis
ABSTRACT Background Fatigue is among the most common symptoms and one of the main factors determining the quality of life in multiple sclerosis (MS). However, the neurobiological mechanisms underlying fatigue are not fully understood. Here we studied lesion locations and their connections in individuals with MS, aiming to identify brain networks ...
Olli Likitalo +12 more
wiley +1 more source
Embedding ethics up front in AI and robotics: evidence from future engineers. [PDF]
Oostveen AM, Eimontaite I.
europepmc +1 more source
Practising Applied Ethics with philosophical integrity: the case of Business Ethics [PDF]
Deon Rossouw
openalex +1 more source
ABSTRACT Objective This study aims to identify both fluid and neuroimaging biomarkers for CSF1R‐RD that can inform the optimal timing of treatment administration to maximize therapeutic benefit, while also providing sensitive quantitative measurements to monitor disease progression.
Tomasz Chmiela +13 more
wiley +1 more source
Ethical Conflicts and Knowledge of the Code of Ethics Among Occupational Therapists in Spain. [PDF]
Emeric-Méaulle D +2 more
europepmc +1 more source
Inhibition of Classical and Alternative Complement Pathway by Ravulizumab and Eculizumab
ABSTRACT Objective To explore the feasibility of classical (CH50) and alternative (AH50) complement pathway activity as potential biomarkers for treatment guidance and monitoring during therapy with ravulizumab in patients with generalized myasthenia gravis (gMG) and compare these to therapeutic drug monitoring under eculizumab.
Lea Gerischer +14 more
wiley +1 more source
Construction and validation of the ultra-short version of the Parenting Scale (PS-4). [PDF]
Schmalbach B +4 more
europepmc +1 more source

